GHRP-1

Origin and Structure

GHRP-1 is a synthetic hexapeptide with the sequence Ala-His-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂, historically one of the earliest members of the growth hormone releasing peptide family. It emerged from the Cyril Bowers laboratory in the 1980s as part of the same line of work that produced GHRP-6. The nomenclature is a source of some confusion — in the primary literature "GHRP-1" sometimes refers to the initial lead compound in the Bowers program rather than a distinct commercialized analogue, and the hexapeptide now sold as "GHRP-1" in research-chemical channels sits historically between the earliest Tulane leads and the better-characterized GHRP-2 and GHRP-6.

GHRP-1 is the least commercially visible of the first-generation GHRPs. Unlike GHRP-6 (which became a research tool for ghrelin biology), GHRP-2 (which reached approval in Japan as a diagnostic), or hexarelin (which built a cardiology research program), GHRP-1 never acquired a distinctive clinical or research niche, and the published pharmacology is correspondingly sparse.

Mechanism of Action

Like every compound in its class, GHRP-1 binds the ghrelin receptor (GHSR-1a) on pituitary somatotrophs to produce GH release. Potency in head-to-head pharmacodynamic work is generally lower than GHRP-2 and comparable to or slightly below GHRP-6. The cortisol, prolactin, and appetite profile is broadly similar to the rest of the first-generation GHRPs — modest cortisol and prolactin elevations at GH-effective doses, and meaningful appetite stimulation driven by arcuate GHSR-1a activation, though less intense than with GHRP-6.

There is no known non-GHSR mechanism for GHRP-1 — no CD36 activity of the sort that distinguishes hexarelin, and no differentiation from the class on receptor selectivity.

Clinical Evidence

The human clinical evidence base for GHRP-1 is very thin:

• Early pharmacodynamic studies. Small healthy-volunteer trials in the early 1990s characterized the GH response curve at various doses and established that GHRP-1 could serve as a GH stimulation probe, but it was superseded in that role by GHRP-2.
• No advanced clinical development. Unlike its better-known siblings, GHRP-1 did not enter a sustained pharmaceutical development program. There are no Phase 2 or Phase 3 trials in any indication, and no regulatory filings on record.
• No recent academic activity. The peer-reviewed literature on GHRP-1 is dominated by papers from the 1990s, with almost no new work in the past two decades.

In practical terms, GHRP-1 is best understood as a historical stepping stone rather than a current research or clinical tool. Any claimed advantages over the better-characterized GHRPs are not supported by contemporary evidence.

Practical Considerations

Research-use protocols that do exist mirror the broader GHRP class: 100-300 mcg subcutaneously, two to three times daily, dosed fasted to avoid glucose- and amino-acid-mediated blunting of ghrelin-receptor response. Cycle lengths of 8-12 weeks are typical, with rest intervals to manage the receptor desensitization that affects every member of the class.

Because the specific evidence base for GHRP-1 is so limited, most research-use practitioners favor better-characterized alternatives — ipamorelin for cortisol/prolactin-clean GH release, GHRP-2 for maximum GH potency, or hexarelin for short-cycle cardiovascular-adjacent research. Our GHRH-plus-GHRP stacking explainer walks through the logic of combining these agents.

Safety and Regulatory Status

Reported side effects in the available literature are consistent with the rest of the class: transient flushing, injection-site reactions, mild headache, appetite stimulation, and cortisol/prolactin elevations that are clinically modest but detectable. The near-total absence of contemporary human data means long-term safety is effectively unknown — not because signals have emerged, but because the compound has not been systematically studied recently enough to generate them.

GHRP-1 is not FDA-approved for any indication. It is captured by the WADA prohibited list at all times (class S2, Peptide Hormones), along with every other GH secretagogue. Supply is through research-chemical vendors; this is a niche compound with a niche market and correspondingly narrow supply-chain visibility.